Against allergies
The vaccine for allergy prevention has entered preclinical trials
It was developed within the framework of the Russian-Austrian project
An innovative vaccine for the prevention of birch pollen allergy and cross-food allergy, developed as part of a joint Russian-Austrian project, has reached the stage of preclinical trials. This was announced by the head of the Federal Medical and Biological Agency (FMBA) of Russia Vladimir Uiba on the eve of the 15th anniversary of the organization to the portal "The Future of Russia. National Projects", which is operated by TASS.
"There is a unique development – a joint project of Russian and Austrian scientists, which is carried out on the basis of the FSBI "SSC Institute of Immunology" of the FMBA of Russia as part of a megagrant under the leadership of the leading scientist of the Vienna Medical University, Professor Rudolf Valenta, dedicated to the development of innovative diagnostic test systems of allergy to birch pollen and a fundamentally new recombinant vaccine for the prevention and treatment of allergy to birch pollen and cross-food allergies. At the moment, preclinical trials of this innovative vaccine are beginning," the head of the FMBA said.
According to him, the peculiarity of this vaccine is that it will be personalized. "The created vaccines induce the production of allergen-specific antibodies and, as a result, immediately block allergic inflammation. They are already based on the personal capabilities or responses of a particular person. In fact, it will be a personal medicine that has passed all the necessary registration and certification," he explained.
Portal "Eternal youth" http://vechnayamolodost.ru